Graham Little–Piccardi–Lassueur syndrome in a patient with androgen insensitivity syndrome

J. Donovan

DOI: https://doi.org/10.1111/ijd.13100

2016-04-01

International Journal of Dermatology

Abstract:Graham Little–Piccardi–Lassueur syndrome (GLPLS) is characterized by the triad of cicatricial scalp alopecia, keratosis pilaris-like eruption on the trunk and extremities, and non-scarring hair loss of the pubis and axillae. GLPLS was first reported in 1914 and since then, approximately 40 reports have appeared in the literature. The syndrome is currently classified by the North American Hair Research Society as a subtype of lichen planopilaris. A single previous reported case in 2004 highlighted the possible association between GLPLS and androgen insensitivity syndrome (testicular feminization). Herein, a second case of GLPLS associated with androgen insensitivity is reported. An approximately 40-year-old woman previously diagnosed complete androgen insensitivity syndrome was referred for the evaluation of hair loss. Keratosis pilaris began on the arms and legs in the patient’s teen years and was followed by scalp hair loss beginning on the crown in the early 20s. The scalp was pruritic in the areas of hair loss. There was no history of atopic dermatitis. Current medications included an ethinyl estradiol-levonorgestrel containing oral contraceptive. The patient had previously been using conjugated estrogens and medroxyprogesterone acetate following gonadectomy. Examination revealed a tall and phenotypically female patient. The patient had an approximately 25 cm 9 25 cm area of nearly complete scarring alopecia affecting the vertex and mid-scalp (Fig. 1). At the periphery of the scarred area, there were hair follicles with perifollicular erythema and scale. The pull test in this area was positive for anagen hairs. Facial hair was not present, and axillary and pubic hairs were sparse. A reduction in eyebrow hair density was noted. A keratosis pilaris-like eruption was present on the arms (Fig. 2), legs, and scattered on the trunk. A 4 mm punch biopsy from the scalp revealed extensive scarring. Perifollicular fibrosis and a perifollicular inflammatory infiltrate of lymphocytes were present in a manner consistent with the diagnosis of lichen planopilaris. There were no superficial or deep inflammatory infiltrates to suggest discoid lupus. The basement membrane was not thickened, and there were not epidermal interface changes. Neutrophils were not seen. Blood work revealed that the hemoglobin level was normal (141 g/l) as was serum ferritin (157 lg/l) and thyroid-stimulating hormone (1.84 mIU/l). The follicle-stimulating hormone level was elevated at 57 IU/l, and the estradiol level was low at 47 pmol/l. Testosterone was consistently low following previous gonadectomy at 0.7 nmol/l. Treatment was initiated with hydroxychloroquine 200 mg orally twice daily, intralesional triamcinolone acetonide (5 mg/ml up to 4 ml every 2–4 months), and topical clobetasol propionate 0.05% lotion but provided only minimal symptom improvement over a 6-month period. The addition of pioglitazone 15 mg orally once Figure 1 Scarring alopecia affecting the mid scalp and vertex scalp in a patient with androgen insensitivity syndrome. Perifollicular erythema is present around many of the remaining hairs. A biopsy confirmed the diagnosis of lichen planopilaris